Centessa Pharmaceuticals (NASDAQ:CNTA) Trading Up 6.3%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) rose 6.3% on Thursday . The stock traded as high as $11.92 and last traded at $11.85. Approximately 67,807 shares were traded during trading, a decline of 82% from the average daily volume of 370,981 shares. The stock had previously closed at $11.15.

Analyst Ratings Changes

Separately, BMO Capital Markets reissued an “outperform” rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Centessa Pharmaceuticals Stock Down 4.6 %

The company has a current ratio of 8.00, a quick ratio of 8.00 and a debt-to-equity ratio of 0.32. The company has a 50-day simple moving average of $10.68 and a 200 day simple moving average of $8.25. The company has a market cap of $1.11 billion, a P/E ratio of -7.21 and a beta of 1.38.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 51,160 shares of the stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total transaction of $607,780.80. Following the transaction, the insider now owns 71,525 shares of the company’s stock, valued at approximately $849,717. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, SVP Harris Rotman sold 4,267 shares of the company’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $8.10, for a total transaction of $34,562.70. Following the completion of the sale, the senior vice president now directly owns 62,625 shares in the company, valued at approximately $507,262.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Karen M. Anderson sold 51,160 shares of the company’s stock in a transaction on Monday, March 25th. The stock was sold at an average price of $11.88, for a total value of $607,780.80. Following the sale, the insider now owns 71,525 shares of the company’s stock, valued at $849,717. The disclosure for this sale can be found here. Corporate insiders own 11.54% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Quarry LP purchased a new stake in Centessa Pharmaceuticals in the fourth quarter valued at about $48,000. China Universal Asset Management Co. Ltd. raised its stake in Centessa Pharmaceuticals by 371.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after buying an additional 5,037 shares during the last quarter. Barclays PLC purchased a new stake in Centessa Pharmaceuticals in the first quarter valued at about $25,000. Prelude Capital Management LLC purchased a new stake in Centessa Pharmaceuticals in the first quarter valued at about $102,000. Finally, Susquehanna International Group LLP purchased a new stake in Centessa Pharmaceuticals in the first quarter valued at about $49,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.